Efficacy and adverse events of continuous l-asparaginase administration for canine large cell lymphoma of presumed gastrointestinal origin.

Abstract

We examined the efficacy and adverse events of continuous l-asparaginase administration in dogs with large cell lymphoma of presumedgastrointestinal (GI) origin. We retrospectively reviewed medical records of dogs with large cell lymphoma of presumed GI origin treated with continuous l-asparaginase administration from 2009 to 2018. We collected information on the signalment, lesion site, complete blood count, serum biochemical profile, diagnostic imaging findings, cytological and histopathological findings, immunophenotype, l-asparaginase administration frequency, treatment response, adverse events, rescue protocol, and patient outcomes. Clinical outcomes were assessed using medical records or by contacting the owner or referring veterinarian. Thirty-two dogs with large cell lymphoma of presumed GI origin received weekly l-asparaginase administration. The median number of l-asparaginase injections was seven (range: 1-30). Although two of the 32 dogs had GI toxicity of grade 3 or higher, none developed a hypersensitivity reaction. The response rate based on ultrasonographic findings was 18/32 (56%) and that based on clinical signs was 30/32 (94%). The median overall progression-free survival was 50 days (range: 2-214 days), and median overall survival was 147 days (range: 2-482 days). Adverse events associated with continuous l-asparaginase administration were rare. Clinical signs at diagnosis improved in most cases. Based on these results, continuous l-asparaginase administration appears to be a reasonable treatment option for dogs with large cell lymphoma of presumed GI origin.

• Authors: Taisuke Nakagawa, Mari Kojima, Koichi Ohno, James K Chambers, Kazuyuki Uchida, Aki Ohmi, Yuko Goto-Koshino, Hirotaka Tomiyasu, Hajime Tsujimoto
• Journal: Veterinary and comparative oncology (Vet Comp Oncol) Vol. 20 Issue 1 Pg. 102-108 (Mar 2022) ISSN: 1476-5829 [Electronic] England
• PMID: 34213084 (Publication Type: Journal Article)
• Copyright: © 2021 John Wiley & Sons Ltd.

Chemical References

• Asparaginase

Topics

• Animals
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Asparaginase (administration & dosage, adverse effects)
• Dog Diseases (chemically induced, drug therapy)
• Dogs
• Lymphoma (veterinary)
• Lymphoma, Non-Hodgkin (drug therapy, veterinary)
• Retrospective Studies